Eisai (TYO:4523) and Biogen have launched the LEQEMBI Pen, a subcutaneous formulation of lecanemab, in Japan following its listing on Japan's National Health Insurance drug price list on Friday.
Japan becomes the second country after the United States to launch the subcutaneous version of LEQEMBI, which received approval as a new route of administration in September, according to a Tokyo bourse filing on Friday.
The autoinjector formulation allows either patient self-administration or administration by a care partner using two pens, with a total of 500 mg, once weekly.
With this launch, LEQEMBI treatment now offers a once-weekly subcutaneous option alongside the existing intravenous administration every two weeks in a medical facility.
Comments